Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Wednesday. Discover the stocks that are generating the highest trading volume and driving market activity.
Shares of scientific instruments company Waters Corporation (NYSE:WAT)
jumped 3.2% in the morning session after Rothschild & Co initiated coverage on the stock with a 'Buy' rating and a $390 price target.
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by the company's recent strategic guidance, which forecasts over $5 billion in potential annual peak sales from its robust pipeline of
Washington D.C., October 8, 2025 – The U.S. federal government remains in the throes of a shutdown, now entering its second week, as lawmakers in Washington continue to grapple with a stalemate over federal funding for Fiscal Year 2026. This ongoing budgetary impasse, which commenced on October 1, 2025,
Pfizer stock is moving higher after being named part of the TrumpRx platform; but two other biopharma companies may offer better long-term growth potential
Investors reacted to the company’s leadership shake-up and new data from its ulcerative colitis therapy Omvoh showing sustained remission over four years.
Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest.
Shares of healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL)
fell 4.4% in the morning session after Citigroup analyst Patrick Donnelly downgraded the stock to 'Neutral' from 'Buy' and lowered the price target. The firm cut its price projection for QuidelOrtho to $33 from $40, a reduction of 17.5%. This adjustment by Citigroup reflected a change in the firm's outlook on the company's stock performance. The downgrade and price target cut highlighted concerns about QuidelOrtho's near-term growth prospects.
BALA CYNWYD, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Pfizer entered into a major agreement with the U.S. government to produce more affordable drugs for Americans. However, the stock’s outlook is still cloudy.
Eli Lilly just got great news, courtesy of Pfizer and Trump, leading shares to their highest level in five months. Its rally may just be getting started.
As the S&P 500 and Nasdaq Composite continue their relentless climb to uncharted record highs in early October 2025, a fascinating and somewhat contradictory narrative is unfolding within the traditionally stable defensive sectors. While the broader market celebrates robust gains, propelled largely by the technology and artificial intelligence boom,
Washington D.C., October 6, 2025 – The American labor market appears to have hit a significant speed bump, with Moody's Analytics reporting "essentially no job growth" for the U.S. in September 2025. This concerning assessment comes at a critical juncture for the economy, compounded by an ongoing federal government
Lockheed’s defense backlog, Pfizer’s biotech expansion, and Schlumberger’s energy contracts make for safe and potentially lucrative dividend plays heading into year-end.
The global financial landscape has been significantly reshaped by a relentless wave of U.S. tariff announcements throughout 2025, sending shockwaves across major indices, currency markets, and commodity prices. These aggressive trade measures, largely spearheaded by the newly inaugurated Trump administration, alongside some preceding adjustments from the Biden era, signal
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Monday and uncover the stocks that are leading the way in terms of trading volume and market attention.
